Hyperphosphataemia Clinical Trial
Official title:
Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease
The main purpose of this study is to see whether PT20 can help people with a high level of phosphate in their blood (called Hyperphosphatemia) that are being treated with dialysis for kidney disease.
PT20 represents a mechanism to address many of the limitations associated with current
phosphate binding agents. The available clinical and non clinical evidence suggests that PT20
binds phosphate and prevents its uptake more efficiently than other phosphate binding drugs
and may therefore either reduce the pill burden associated with controlling phosphate levels,
or result in lower phosphate levels with the same pill burden.
The this study is the first to investigate the efficacy and safety of PT20 in subjects with
dialysis-dependent chronic kidney disease (CKD).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01857024 -
Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia
|
N/A | |
| Completed |
NCT01424787 -
Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering)
|
N/A |